Overview

Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Multidose, Open-label, Multi-center Study to examine the steady state pharmacokinetics of TPM XR, as well as, safety and tolerability of repeated oral dosing in pediatric subjects with epilepsy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc.